Carlson E
Infect Immun. 1983 Oct;42(1):285-92. doi: 10.1128/iai.42.1.285-292.1983.
Nine Staphylococcus aureus strains isolated from patients with toxic shock syndrome (TSS), two strains from non-disease-associated sources, and four strains from disease (not TSS)-associated sources were characterized for the intraperitoneal dose necessary to kill 50% of exposed animals (LD50) and toxic shock toxin production and studied for synergistic effects on mouse mortality and morbidity when combined with a sublethal dose of Candida albicans and inoculated intraperitoneally. Representative toxic shock toxin-producing strains (free of other enterotoxins) exhibited the following unique set of characteristics when inoculated intraperitoneally into mice and compared with all other strains tested: (i) lowest virulence when inoculated alone into mice as determined by the LD50; (ii) greatest synergistic decrease in LD50 (up to 70,000-fold as compared to up to 200-fold for other strains) when combined with C. albicans and injected intraperitoneally; and (iii) induced a characteristic, dose-independent, temporal death pattern in dually injected animals. When sublethal dual doses were used, animals receiving disease (TSS and not TSS)-associated S. aureus in combination with C. albicans developed symptoms, but some differences in symptomatologies, depending on the strain, were observed. The symptoms included conjunctivitis; gastrointestinal, neurological, and circulatory abnormalities; rash followed by desquamation; and patchy baldness. Although overlap in symptoms between animal treatment groups was observed, certain symptoms (neurological sequeae and petechial hemorrhages) were observed only in animals inoculated with a specific S. aureus strain combined with C. albicans. Animals receiving sublethal dual doses, which included non-disease-associated S. aureus, did not develop symptoms. When Staphylococcus epidermidis was combined with C. albicans and inoculated into mice, no synergistic effects on morbidity or mortality were observed.
从中毒性休克综合征(TSS)患者中分离出9株金黄色葡萄球菌菌株,从非疾病相关来源分离出2株,从疾病(非TSS)相关来源分离出4株,对其进行了杀死50%受试动物所需的腹腔内剂量(LD50)及中毒性休克毒素产生情况的鉴定,并研究了与亚致死剂量白色念珠菌联合腹腔接种时对小鼠死亡率和发病率的协同作用。具有代表性的产中毒性休克毒素菌株(不含其他肠毒素)腹腔接种小鼠后,与所有其他受试菌株相比,呈现出以下一组独特特征:(i)单独接种小鼠时,根据LD50确定其毒力最低;(ii)与白色念珠菌联合腹腔注射时,LD50的协同降低幅度最大(与其他菌株高达200倍的降低幅度相比,高达70000倍);(iii)在双重注射的动物中诱导出一种特征性的、剂量无关的、随时间变化的死亡模式。使用亚致死双重剂量时,接受疾病(TSS及非TSS)相关金黄色葡萄球菌与白色念珠菌联合接种的动物出现了症状,但根据菌株不同,在症状表现上存在一些差异。症状包括结膜炎;胃肠道、神经和循环系统异常;皮疹后脱皮;以及斑秃。虽然在动物治疗组之间观察到症状有重叠,但某些症状(神经后遗症和瘀点出血)仅在接种特定金黄色葡萄球菌菌株与白色念珠菌联合制剂的动物中出现。接受包含非疾病相关金黄色葡萄球菌的亚致死双重剂量的动物未出现症状。当表皮葡萄球菌与白色念珠菌联合接种小鼠时,未观察到对发病率或死亡率的协同作用。